Thrombomodulin (TM), via its lectin-like domain (LLD), exhibits anti-inflammatory properties partly by sequestering the pro-inflammatory cytokine, high-mobility group box 1 (HMGB1). Since myocardial damage after ischaemia and reperfusion is mediated by inflammation, we evaluated the cardioprotective effects of the LLD of TM. Using an in vivo mouse model of transient ischaemia and in vitro models of cardiomyocyte hypoxia, we assessed the ability of the LLD to suppress HMGB1-mediated activation of the receptors, receptor for advanced glycation endproducts (RAGEs) and Toll-like receptors (TLRs) 2 and 4.
Introduction
Major features of ischaemic myocardial injury are cardiomyocyte death and scar formation. 1 It is generally accepted that tissue damage is best limited by restoring perfusion to the infarcted myocardium through early revascularization. However, reperfusion induces inflammation, causing additional damage that exceeds the initial ischaemic injury. 2 Since complete suppression of inflammation leads to limited wound healing and cardiac rupture, 3 therapeutic strategies aiming for reducing the inflammatory process without preventing it are needed. Thrombomodulin (TM) is a multifunctional transmembrane glycoprotein receptor that is well known for its function as a cofactor for † These authors contributed equally.
the thrombin-mediated generation of activated protein C and activation of thrombin-activatable fibrinolysis inhibitor, which in turn have anticoagulant, anti-inflammatory, anti-apoptotic, and anti-fibrinolytic properties. 4 Beyond its role in haemostasis, TM has distinct anti-inflammatory properties mediated by its N-terminal lectin-like domain (LLD). The LLD protects tissues from pro-inflammatory stimuli by interfering with adhesion molecule expression, cytokine release, and leucocyte recruitment. These effects are associated with suppressed activation of mitogen-activated protein kinase, which leads to suppression of pro-inflammatory nuclear factor-kB pathways. 5 Mice lacking the LLD of TM (TM LeD/LeD ) exhibit an augmented response to endotoxemia, inflammatory arthritis, lung injury, and short-term myocardial reperfusion injury. 5 -7 It has been proposed that high-mobility group box 1 (HMGB1) is a ligand for the LLD of TM.
8 HMGB1 was initially identified as a highly conserved, non-chromosomal nuclear protein that maintains nucleosomal structure and regulates gene transcription. 9, 10 HMGB1 can be passively released from apoptotic and necrotic cells or can be actively secreted. 10 -14 HMGB1 is a pro-inflammatory cytokine engaging receptors of the family of pattern recognition receptors. These include the receptor for advanced glycation endproducts (RAGEs) and Toll-like receptors 2 and 4 (TLR2 and TLR4, respectively). 10 A growing body of evidence suggests that HMGB1 acts as an inflammatory mediator in ischaemic heart disease and conveys ischaemic myocardial damage. 15 -19 HMGB1 can be sequestered by the LLD of TM, which effectively prevents HMGB1 from binding to one or all of its target receptors. 8 We have previously shown that the lack of the LLD of TM in mice is deleterious early after myocardial ischaemia. 5 The mechanism of the anti-inflammatory effects of the LLD of TM in post-ischaemic myocardium remains, however, elusive. Since it is known that HMGB1 can interact with the LLD of TM in vitro, we analysed the role of the LLD of TM in modulating HMGB1-mediated myocardial damage during myocardial ischaemia with reperfusion (MI/R) by using the TM LeD/LeD mouse model.
To evaluate the HMGB1-LLD axis as a therapeutic target for cardioprotection, we identified the receptor responsible for HMGB1-mediated damage on cardiomyocytes and assessed in vivo the benefit of therapeutically targeting each of the components.
Methods

Murine model of MI/R injury
Mice lacking the N-terminal LLD of TM (TM LeD/LeD mice) were generated as previously described. 5 Strain-, age-, and sex-matched TM LeD/LeD mice and their wild-type (WT) counterparts were used. Myocardial ischaemia was induced with approval of the Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit (Oldenburg, Germany) and in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health. Mice were anaesthetized with isoflurane (2 vol% in air) and ventilated through an endotracheal tube with a small rodent respirator (MiniVent Type 845, Hugo Sachs Elektronik, March-Hugstetten, Germany). For MI/R, the left anterior descending coronary artery (LAD) was occluded for 30 min by ligation with 7-0 silk, followed by 24 h and 7 days of reperfusion. MI was induced by permanent ligation of the LAD without reopening the LAD. 3 Analgesia was provided using metamizol administered with the drinking water for a dose of 200 mg/kg. For infarct size measurements, animals were re-anaesthetized and perfused with 0.9% saline through the abdominal aorta. The coronary ligation was retied and 2% Coomassie Blue injected to delineate the area at risk (AAR).
The heart was sectioned into five equal slices and immersed in 2,3,5-triphenyl-tetrazolium chloride (TTC, Sigma, Taufkirchen, Germany) at 378C for 10 min. Left ventricular area, AAR, and area of infarction were determined morphometrically using NIH Image as previously published.
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For leucocyte depletion, 2 mg of hydroxycarbamide per gram body weight (20 mg in 100 mL of 0.9% saline) was injected intraperitoneally 2 days before ligation, with another 1 mg/g on the following day (Bristol-Myers Squibb, Brussels, Belgium). Hydroxycarbamide induced leucopenia and white blood cell counts of the myeloid line dropped ,10% of control with no differences between WT and TM LeD/LeD mice.
Real-time RT-PCR
Total RNA was extracted from tissues and cells using TRItidy reagent (Applichem, Darmstadt, Germany). All reagents were from Eurogentec (Cologne, Germany). Samples were run on a real-time PCR cycler (Rotogene 3000, Corbett Life Science, Hilden, Germany). Signals were generated by MESA-GREEN incorporation into the amplified DNA and normalized to hypoxanthin-phosphoribosyl-transferase or GAPDH gene expression.
Immunohistochemistry
Hearts were perfusion-fixed (4% paraformaldehyde), harvested from animals, and paraffin-embedded. 
Western blot
Protein lysates (5 -40 mg) from non-ischaemic and ischaemic mouse myocardium or from cultured cells were electrophoretically separated and identified by the western blot using the following primary antibodies: HMGB1, human TM (Abcam), cleaved caspase-3 (Cell Signaling, Frankfurt, Germany), and c-Myc (Abcam). Horseradish peroxidase-coupled rabbit or mouse IgGs were used as secondary antibodies. Membranes were re-probed with anti-GAPDH, anti-b-tubulin, and anti-lamin A/C (Cell Signaling) to confirm equal protein loading.
Cell culture
Primary mouse embryonic fibroblasts were immortalized by the 3T3 protocol 21 and activated after 1 day of serum starvation with 10 ng/mL of transforming growth factor-b (TGF-b) (R&D Systems, Wiesbaden, Germany) overnight. Immortalized murine endothelial cells (fEnd.5) 20 were exposed to hypoxia with reoxygenation (H/R) for 3 h in hypoxia buffer before buffers were switched and normoxia was achieved for 1 h as described earlier 22 and in Supplementary material online. Neonatal ventricular cardiomyocytes from WT and TM LeD/LeD mice and Sprague -Dawley rats (Charles River, Sulzfeld, Germany) were isolated from 1-to 3-day-old animals using the method of collagenase Type II enzymatic digestion. 22, 23 New born pups were rapidly decapitated using sharp scissors. Cardiomyocytes were exposed to H/R. Twenty-four hours before H/R was started, rat cardiomyocytes were transfected with siRNAs specific for TLR2, TLR4, and RAGE (Applied Biosystems, Darmstadt, Germany) by using lipofectamine RNAiMAX (Invitrogen, Karlsruhe, Germany). HMGB1 (500 ng/mL) (R&D Systems) was added to the media before inducing hypoxia.
Subcellular localization of HMGB1
HL-1 cells (mouse cardiomyoblasts) were cultured as described. 24 cDNAs encoding full-length human TM or TM lacking the LLD (amino acid residues 19 -157) were subcloned into pcDNA3.1 (Invitrogen, Merelbeke, Belgium) HMGB1-induced cardiomyocyte apoptosis through TLR2 is counteracted by thrombomodulin's lectin-like domain resulting in pcDNA vector expressing full-length human TM (pcDNA-hTM) and pcDNA vector expressing TM lacking the LLD (pcDNA-hTM-DLLD), respectively. Ten microgram of either construct was used to transfect HL-1 cells using Fugene HD (Roche Diagnostics, Mannheim, Germany). Forty-eight hours after transfection, cells were serum-starved for 24 h and incubated with HMGB1 (500 ng/mL) for 2 h. Membrane, cytosolic, and nuclear fractions were prepared by ultracentrifugation as described, 25 and purity of fractions was tested by blotting with corresponding markers. 26 Cell culture supernatant was collected and concentrated 10-fold using Vivaspin 10 000 MWCO columns (Sartorius, Goettingen, Germany). HMGB1 protein levels in the different subcellular fractions and in the supernatant were analysed by western blot.
Immunoprecipitation
Cell culture supernatant from HL1-transfection experiments was incubated with anti-HMGB1 (Abcam), pre-incubated with TrueBlot anti-rabbit Ig IP Beads (eBioscience, San Diego, USA) while rocking at 48C overnight. Immunoprecipitates were washed three times with RIPA buffer, resuspended in 30 mL of 1× Laemmli sample buffer, and then resolved by SDS -PAGE.
Anti-HMGB1 and anti-TLR2 antibody treatments
To block the function of HMGB1 or TLR2 in vivo, neutralizing polyclonal chicken IgY anti-HMGB1 antibody (200 mg/mouse: Shino-Test Corporation, Sagamihara, Japan) or neutralizing mouse monoclonal IgG anti-TLR2 antibody (70 mg/mouse; BioLegend, San Diego, CA, USA) was injected intraperitoneally in TM LeD/LeD mice 60 min before ligation. A chicken IgY antibody (Shino-Test Corporation) was used as a control of the anti-HMGB1 antibody. Apoptosis was evaluated by quantification of cleaved caspase-3 protein by western blot. Plasma levels of troponin T just prior to sacrifice were quantified using the Cardiac T point-of-care kit (Roche Diagnostics). 27 
Hydrodynamic transfection for therapeutic gene delivery
For in vivo gene delivery, the cDNA encoding the first 155 amino acids of the LLD of murine TM was subcloned into pSecTag2HygroA-CMV (Invitrogen, Merelbeke, Belgium) resulting in pSec-LLD, as described previously. 6 For hydrodynamic transfection, the expression vectors pSec and pSec-LLD (40 mg in 2 mL of 0.9% saline) were injected within 5 s via a 27G tail vein catheter 24 h before induction of MI/R injury. After 24 h of reperfusion, AAR and area of infarction were measured by TTC/Coomassie staining. Transfection efficiency was tested by the western blot of serum samples for the c-Myc-tagged fusion protein.
Statistical analysis
Data are presented as mean + SEM. Whenever data displayed non-Gaussian distributions or significantly different SDs, Kruskal -Wallis test followed by the Mann-Whitney-U test, otherwise analysis of variance (ANOVA) followed by the t-test, was performed. In the cardiomyocyte experiment testing the effect of different silencing approaches and treatment with HMGB1 during H/R ( Figure 5D ), a two-way ANOVA with the Bonferroni post-test was used (Prism, GraphPad, Inc., San Diego, CA, USA). In experiments with multiple comparisons of multiple groups, Dunnett's test was applied following ANOVAs. All authors had full access to the data and take full responsibility for their integrity. All authors have read and agreed to the manuscript as written.
Results
Lack of LLD aggravates myocardial inflammation after transient ischaemia
After 30 min of ischaemia followed by 24 h of reperfusion, myocardial infarcts were significantly larger in TM LeD/LeD mice when compared with WT (P , 0.01, Figure 1A ). Accumulation of specific mRNAs for the pro-inflammatory cytokines tumor necrosis factor-a and interleukin-1b were significantly increased in TM LeD/LeD vs. WT hearts (P , 0.05, Figure 1B ). There were also significantly more CD45-positive leukocytes/mm 2 ( Figure 1C ) in TM LeD/LeD vs. WT mice (P , 0.05). We assessed the contribution of leukocytes to myocardial damage 20 by depleting leucocytes in the TM LeD/LeD and WT mice using hydroxycarbamide. The extent of leucopenia achieved was similar in both genotypes. Leucocyte depletion resulted in smaller infarcts in both the TM LeD/LeD and WT mice 24 h after MI. However, even after leucocyte depletion, there still remained a significant difference in infarct size between TM LeD/LeD and WT mice (P , 0.01), suggesting that the lack of the LLD results in adverse effects on the myocardium during reperfusion that are in addition to those involving leucocyte recruitment ( Figure 1D ).
Lack of the LLD aggravates apoptosis in vivo and in vitro
The role of the LLD on apoptotic cell death in vivo was analysed by TUNEL and quantification of cleaved caspase-3 in the AAR. The HMGB1 staining was mainly restricted to the nuclei with faint cytosolic and membrane-associated staining, and more pronounced diffuse extracellular staining in TM LeD/LeD mice ( Figure 3A and B) . In western blots of ischaemic heart lysates ( Figure 3D) , there was a two-fold increase in HMGB1 levels in TM LeD/LeD mice compared with WT (P , 0.05).
Cellular source of HMGB1
To test whether increased HMGB1 levels in the infarct zone of TM LeD/LeD mice can be attributed to the increased number of inflammatory cells, we carried out double stainings for HMGB1 and PMN ( Figure 4A and C) and HMGB1 with WGA ( Figure 4B and D) . As expected we found HMGB1 to be expressed in PMNs (arrows), but we also observed HMGB1 staining in the nuclei of cardiomyocytes (arrowheads) and to a lesser extent in other nuclei, most likely endothelial cells and fibroblasts. Quantification of HMGB1 expression on immunohistochemically stained sections was limited in sensitivity. Using in vitro approaches, we therefore examined, which of the isolated cell types found in the heart increases HMGB1 expression after H/R. Cultured endothelial cells and neonatal rat cardiomyoctes (NRCMs) were exposed to H/R, and HMGB1 expression was monitored by western blot. Since fibroblasts are resistant to hypoxia, we used TGF-b as a stressor and HMGB1 inducer ( Figure 4E) . 28 Neither fibroblasts nor endothelial cells showed a significant increase in HMGB1 expression. However, in NRCM, expression of HMGB1 was significantly enhanced (P , 0.05) by H/R, suggesting that cardiomyocytes, apart from leukocytes, represent an additional source of HMGB1 that is elevated in ischaemic hearts.
Cellular localization of HMGB1
HMGB1 must be released from its intracellular source to exert pro-inflammatory effects. We used HL-1 cardiomyoblasts to determine whether the LLD of TM regulates subcellular localization, release, and/ or bioavailability of HMGB1. HL-1 cardiomyoblasts were transfected with pcDNA-hTM (human TM) and pcDNA-hTM-DLLD (human TM lacking the LLD) to achieve high expression of hTM and hTM-DLLD, respectively, by 72 h ( Figure 4F ). No differences in HMGB1 expression were observed in cytosolic and nuclear fractions, suggesting that the endogenous HMGB1 pool was not dependent on the integrity of TM. After a 2-h incubation of HL-1 cells with HMGB1 ( Figure 4F ), membranebound HMGB1 was increased in hTM-DLLD-expressing cells when compared with cells expressing full-length hTM. At the same time, HMGB1 levels in the supernatants of hTM-DLLD-expressing cells were reduced compared with cells expressing hTM ( Figure 4G ).
The data indicate that the LLD promotes clearance of HMGB1 from the cell surface. Indeed, 2 h after HMGB1 stimulation, co-immunoprecipitation experiments revealed the presence of HMGB1-hTM complexes in the media of hTM-expressing cells ( Figure 4H ).
HMGB1 augments hypoxia-induced apoptosis in cardiomyocytes via TLR2
We next examined the pathways involved in HMGB1-mediated apoptosis in NRCM after hypoxia. HMGB1 caused a significant increase in the number of apoptotic cells as measured by TUNEL and caspase-3 cleavage ( Figure 5A and B, P , 0.01). To determine which of the HMGB1-induced cardiomyocyte apoptosis through TLR2 is counteracted by thrombomodulin's lectin-like domain recognized HMGB1 receptors (TLR2, TLR4, and RAGE) 10 mediates the apoptotic signals, hypoxia-induced apoptosis was examined in NRCMs transfected with the respective siRNAs ( Figure 5C ). siRNA treatment reduced TLR2-and TLR4-to 30% and RAGE-expression to 50% (P , 0.05). The pro-apoptotic effect of HMGB1 after hypoxia (3 h) and reoxygenation (1 h) was only abolished with TLR2-siRNA treatment ( Figure 5D , P , 0.0001). Apoptosis rates were unchanged in TLR4-or RAGE-siRNA-treated cells ( Figure 5D ). Without H/R, TLR2-siRNA had no effect on apoptosis.
Blocking HMGB1 or TLR2 and over expression of LLD protects against MI/R injury
Next, we assessed the effects of neutralization of HMGB1 or TLR2 on the extent of the pro-inflammatory damage in TM LeD/LeD mice. Inhibition of HMGB1 or TLR2 with antibodies administered 60 min before MI/R decreased cellular apoptosis as quantified by caspase-3 cleavage in AAR tissue harvested from TM LeD/LeD mice ( Figure 6A , P , 0.05).
Plasma troponin T was likewise significantly decreased by pre-infusion with anti-HMGB1 and anti-TLR2 antibodies ( Figure 6B , P , 0.05).
In addition, we evaluated whether administration of the LLD of TM could reduce myocardial damage after ischaemia in mice. This was achieved via hydrodynamic gene delivery of a cDNA encoding the fusion protein LLD of TM carrying a c-Myc-tag in WT mice 24 h prior to MI/R. A high level of circulating recombinant protein was confirmed by detection of the c-Myc-tagged LLD in serum samples by western blot ( Figure 6C ). Twenty-four hours after MI/R, the LLD of TM decreased HMGB1 protein to 36% in ischaemic hearts ( Figure 6D , P , 0.05) and reduced the infarct size by .50% ( Figure 6E , P , 0.01).
Lack of the LLD affects infarct healing but not angiogenesis
In the literature, HMGB1 is not only known as an inflammatory mediator in ischaemic heart disease, 18 but also to show beneficial effects on angiogenesis and ventricular function at later time points after infarction. 29 Taking this into account, we analysed the role of LLD on infarct healing, angiogenesis, and ventricular function. Collagen deposition, as well as the number of a-SMA-positive myofibroblasts, is increased 7 days after MI/R in TM LeD/LeD compared with WT mice (P , 0.05), whereas the number of newly formed capillaries were not different ( Figure 7 , Table 1 , and Supplementary material online, Figure S1 ). Since the infarctions after reperfusion injury are small, we assessed the effects of the lack of the LLD of TM after permanent infarction on scar composition. Collagen deposition and the number of capillaries were not different 7 days after permanent myocardial infarction, while myofibroblast numbers were higher in the KO animals ( Figure 7 and (D) HMGB1 protein levels at 24 h after MI/R were examined by western blot. Levels of HMGB1 in myocardial ischaemic tissue were augmented about two-fold in LLD-deficient compared with WT mice (n ¼ 5, P , 0.05).
HMGB1-induced cardiomyocyte apoptosis through TLR2 is counteracted by thrombomodulin's lectin-like domain Supplementary material online, Table S1 ). Using echocardiography, we could observe typical changes of left ventricular function and ventricular wall thickness in both groups, while no obvious differences between TM LeD/LeD and WT mice were detectable (Supplementary material online, Table S2 ).
Discussion
The anti-inflammatory activities of the LLD of TM have previously been reported by our group and others. However, the mechanisms underlying its protective properties in different organ systems and disease entities remain unclear. 5 -7 In addition to its effects on leucocyte recruitment, we report on a leucocyte-independent myocardial protective effect of the LLD of TM that relies on its ability to scavenge and clear the pro-inflammatory cytokine HMGB1, preventing its interaction with TLR2. We have previously shown that mice lacking the LLD of TM develop larger myocardial infarctions as early as 3 h after ischaemia. In this report, we demonstrate that the effect on increased infarct size and apoptosis persists 24 h after MI/R, and that administration of soluble LLD of TM is protective. Leucocyte depletion reduces infarct size in WT and LLD-deficient mice, but this smaller difference between the genotypes remains significant. Thus, the LLD of TM confers protection via leucocyte-dependent and -independent mechanisms. We determined that the latter effect was mediated by the capacity of the LLD of TM to abrogate the noxious properties of HMGB1. Based on our in vitro studies, it is likely that the relevant source of HMGB1 release in the setting of MI/R is the cardiomyocyte, and that the key pathway involved is TLR2.
In a model of MI/R injury, HMGB1 has been reported to promote inflammation by binding to RAGE. 18 The relevance of this pathway in the context of protection afforded by the LLD of TM has also been demonstrated in a model of skin inflammation, where the LLD of TM reduced inflammation by interfering with HMGB1 binding to RAGE. 8 We have used an in vitro model of H/R and determined that TLR2 is responsible for HMGB1-mediated apoptosis in cardiomyocytes. Furthermore, treatment of TM LeD/LeD mice with HMGB1-and TLR2-blocking antibodies reduces apoptosis and myocardial damage induced by MI/ R, emphasizing the importance of HMGB1 -TLR2 interactions in this pathological setting. These findings are not necessarily contradictory to a previous report showing the importance of HMGB1-RAGE interactions, because the impact of TLR2 was not examined and cardiomyocyte apoptosis was not an endpoint in that particular study. 18 It is quite possible that binding of HMGB1 to different receptors serves different functions during MI/R. Our data also indicate that, during MI/R, the LLD of TM provides protection by scavenging HMGB1, preventing HMGB1 -TLR2 interactions, rather than RAGE or TLR4. Yet, mere binding of HMGB1 to the LLD of TM cannot explain the protective effect of TM in MI/R. We therefore set out to examine the fate of HMGB1 once bound to the LLD of TM. In the absence of the LLD of TM, HMGB1 localization to the cell membrane fraction of cardiomyoblasts was increased. Membrane-bound HMGB1 (D) The effect on hypoxia-mediated apoptosis in NRCM was assessed by TUNEL staining. Co-incubation of hypoxia-treated cardiomyocytes with HMGB1 showed an increase in the number of TUNEL-positive nuclei. siRNA knockdown of TLR2 abolished the pro-apoptotic effect of HMGB1 during H/R. siRNA knockdown of TLR4 and RAGE showed no effect on HMGB1-mediated apoptosis in cardiomyocytes (n ¼ 15).
HMGB1-induced cardiomyocyte apoptosis through TLR2 is counteracted by thrombomodulin's lectin-like domain is thus more readily available for binding to its putative receptors of the pattern recognition type. Unfortunately, for technical reasons, we were unable to co-immunoprecipitate HMGB1 and TLR2 from cell membranes. However, our hypothesis is supported by the observation that, in the presence of full-length TM (i.e. with the LLD intact), LLD-HMGB1 complexes were increased in the supernatant of the cells, suggesting that HMGB1 might be more readily cleared from the site of injury.
The precise mechanisms by which HMGB1 is cleared from the cell surface are, in fact, poorly understood. TM is shed from the cell membrane in inflammatory states. An increased concentration of several soluble fragments derived from the ectodomain of TM can be found in the plasma and urine in sepsis, meningitis, and encephalitis in humans and also in small animals. 30 -32 To the best of our knowledge, studies
have not been performed to determine whether circulating LLD-HMGB1 complexes exist in health and/or disease and if so, how these are cleared from the blood or which function they may still have. It is reasonable to argue, however, that increased circulating levels of the LLD of TM-either endogenous or exogenous-may scavenge HMGB1, thereby antagonizing the adverse effects of HMGB1 in various disease states.
In that respect, administration of recombinant soluble TM in different experimental settings is associated with decreased inflammation and reduced plasma levels of HMGB1. 33, 34 In line with these findings, we
show that mice lacking the LLD of TM have elevated levels of HMGB1 in the heart, and that HMGB1 is not cleared from the membranous fraction of cells that lack the LLD. This is in contrast to cells that express full-length TM. Moreover, administration of the soluble LLD of TM via hydrodynamic gene delivery reduced HMGB1 in myocardial tissue in WT mice. We therefore propose a model whereby TM via its LLD, scavenges HMGB1 as it is released, and the HMGB1 -TM complexes are subsequently shed from the cell surface, thereby clearing HMGB1, reducing its bioavailability to bind to its cognate receptor(s), and thus preventing further tissue damage. HMGB1 has been reported to act as a pro-inflammatory mediator after MI/R, 18 while studies using MI showed a beneficial effect of HMGB1 for left ventricular remodelling, angiogenesis, and infarct healing, 16, 17, 29 suggesting that in the two mouse models and after various time periods HMGB1 is differentially involved. Accordingly, in mice lacking the LLD, we observed augmented inflammation and increased collagen deposition without differences in vascular density or integrity after 7 days of reperfusion, which was confirmed in animals that had undergone permanent ligation of the coronary. Since most of the previous studies analysed HMGB1 effects at 4-6 weeks after MI, it is well possible that, in LLD-deficient mice, differences in myocardial remodelling will still occur at later times. Figure 7 Histological analysis of infarct area 7 days after MI/R and MI. Seven days after MI/R, picrosirius red staining revealed increased collagen deposition in TM LeD/LeD mice (B) compared with WT (A), whereas no differences in collagen deposition could be observed 7 days after MI (C and D). Bar ¼ 100 mm.
The number of myofibroblasts stained with a-SMA (red) is increased in TM LeD/LeD mice (F) compared with WT (E). The number of isolectin B4 stained vessels (red) is not different between WT and TM LeD/LeD mice (G and H ). Bar ¼ 50 mm. Insets show a-SMA (E and F ) and isolectin B4 (G and H ) staining in higher magnification. Bar ¼ 25 mm. Green autofluorescence is shown for better visualization of cellular structures.
HMGB1-induced cardiomyocyte apoptosis through TLR2 is counteracted by thrombomodulin's lectin-like domain Our study is limited by the fact that for leucocyte depletion hydroxycarbamide was used, which is known to show side effects on nitric oxide biology. 3, 20 Since mainly PMNs are recruited into the reperfused injured myocardium at the time point studied, we feel that the results with respect to alterations in the myocardium in this short time can be attributed to the ablation of the myeloid cell line and in PMNs in specific.
In conclusion, our study demonstrates that the LLD of TM confers cardioprotective effects by scavenging HMGB1, thereby preventing cardiomyocyte apoptosis, which is likely mediated via TLR2. Blockade of HMGB1 and TLR2 as well as overexpression of the LLD of TM reduces myocardial damage after MI/R. Therapeutic strategies that target the LLD of TM, HMGB1, and TLR2, as a single strategy or in combination, present novel opportunities to more effectively reduce tissue injury after MI/R. 
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